NCT06855069招募中3 期
A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Hansoh BioMedical R&D Company1 个研究点 分布在 1 个国家目标入组 468 人开始时间: 2025年3月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 468
- 试验地点
- 1
- 主要终点
- Progression-free Survival (PFS) assessed by Blinded Independ Review Committee (BIRC) as per RECIST 1.1
研究概览
简要总结
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Voluntary participation and written informed consent.
- •18 years and older, female.
- •Pathologically diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
- •Patients must have platinum-resistant disease
- •Be able to provide fresh or archived tumor tissue.
- •At least one measurable lesion according to RECIST v1.
- •Eastern Cooperative Oncology Group (ECOG) score: 0-
- •With a life expectancy > 12 weeks.
- •Adequate bone marrow reserve and organ function.
- •Contraception is required during the trial.
排除标准
- •Prior treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload.
- •Previous or co-existing malignancies.
- •Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring clinical intervention.
- •Received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment.
- •Unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.
- •History of severe hypersensitivity reactions to either the drug substances or inactive ingredients of HS-
- •Any serious or uncontrolled medical disorder in the opinion of the investigator that may increase the risk associated with the study participation or study drug administration.
- •Other inappropriate situation considered by the investigator.
研究组 & 干预措施
Treatment group 1: HS-20089
Experimental
干预措施: HS-20089 (Drug)
Treatment group 2: Investigator's choice of chemotherapy
Active Comparator
干预措施: Paclitaxel (Drug)
Treatment group 2: Investigator's choice of chemotherapy
Active Comparator
干预措施: Doxorubicin (Drug)
Treatment group 2: Investigator's choice of chemotherapy
Active Comparator
干预措施: Topotecan (Drug)
结局指标
主要结局
Progression-free Survival (PFS) assessed by Blinded Independ Review Committee (BIRC) as per RECIST 1.1
时间窗: Screening up to study completion, an average of 1 year
次要结局
- Duration of Response (DoR), assessed by site investigator as per RECIST 1.1(Screening up to study completion, an average of 1 year)
- Disease Control Rate (DCR), assessed by site investigator as per RECIST 1.1(Screening up to study completion, an average of 1 year)
- Overall Survival (OS)(Screening up to study completion, an average of 1 year)
- Objective Response Rate (ORR), assessed by site investigator as per RECIST 1.1(Screening up to study completion, an average of 1 year)
- Objective Response Rate (ORR), assessed by BIRC as per RECIST 1.1(Screening up to study completion, an average of 1 year)
- Duration of Response (DoR), assessed by BIRC as per RECIST 1.1(Screening up to study completion, an average of 1 year)
- Disease Control Rate (DCR), assessed by BIRC as per RECIST 1.1(Screening up to study completion, an average of 1 year)
- Adverse Events(Screening up to study completion, an average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCHepatocellular CarcinomaNCT04720716Innovent Biologics (Suzhou) Co. Ltd.344
已完成
3 期
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device OcclusionCatheter ObstructionVascular Access DevicesNCT01958164Boehringer Ingelheim16
已完成
3 期
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNon - Small Cell Lung Cancer NSCLCNCT02352948AstraZeneca597
终止
3 期
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)Myelodysplastic Syndromes(MDS)NCT05709093TJ Biopharma Co., Ltd.10
招募中
3 期
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerUrothelial CarcinomaNCT06592326Mabwell (Shanghai) Bioscience Co., Ltd.460